Nuvo Research to Receive US$6.0 Million of Milestone Payments from Pliaglis® E.U. Approvals
News Jul 20, 2012
Nuvo Research Inc. has announced that Galderma S.A. (Galderma), a global company dedicated to dermatology has received its first three Pliaglis marketing licenses from E.U. countries.
These licenses entitle Nuvo to receive a total of US$6.0 million of milestone payments from its worldwide Pliaglis marketing partner, Galderma.
The milestone payments are due on the earlier of the launch of Pliaglis in the approved countries or 6 months from the date of marketing approval.
The payments are expected in December 2012 (US$5.0 million) and January 2013 (US$1.0 million).
Galderma has advised Nuvo that it expects to launch Pliaglis in the E.U. and other territories in the first half of 2013.
Nuvo previously filed a Marketing Authorization Application (MAA) for the approval of Pliaglis in 16 E.U. countries using the European Decentralized Procedure and on May 4, 2012 received a positive recommendation that Pliaglis is approvable for the indication of producing local dermal anesthesia on intact skin in adults prior to superficial dermatological procedures.
The regulatory process then entered its final phase during which individual countries issue marketing licenses that allow Pliaglis to be marketed in each country.
Nuvo expects to receive marketing licenses from the other E.U. countries over the next 12 months.
"We are extremely pleased that Pliaglis is in the process of being approved in a number of E.U. countries and that Nuvo is receiving a substantial regulatory milestone payment as a result," said Dr. Bradley Galer, President of Nuvo's Pain Group.
Dr. Galer continued, "The upcoming launch of Pliaglis will mean that Nuvo will have 3 growing sources of revenue from globally commercialized topical pain products."
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018